shutterstock_1119823829_sureeporn_teerasatean

Sureeporn Teerasatean / Shutterstock.com

30 November 2020BiotechnologyMuireann Bolger

CMA reveals antitrust investigation into Essential Pharma over bipolar drug

The UK Competition and Markets Authority (CMA) is investigating Essential Pharma over suspicions that the pharmaceutical company contravened competition law by proposing to withdraw the supply of Priadel, a lithium-based medication for bipolar disease.

Already registered?

Login to your account

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

CMA alleges collusion allowed 1,800% hike in Aspen drug pricing

9 October 2019 African drugmaker Aspen was able to increase its prices for fludrocortisone acetate tablets by 1,800% in the UK, as a result of collusion with two other firms, according to the UK’s Competition and Markets Authority.

CMA accuses 4 pharma companies of anti-competitive conduct

24 May 2019 Four pharmaceutical companies allegedly agreed not to compete for the supply of an anti-nausea tablet to the National Health Service, according to objections filed by the UK Competition and Markets Authority.

More on this story

CMA alleges collusion allowed 1,800% hike in Aspen drug pricing

9 October 2019 African drugmaker Aspen was able to increase its prices for fludrocortisone acetate tablets by 1,800% in the UK, as a result of collusion with two other firms, according to the UK’s Competition and Markets Authority.

CMA accuses 4 pharma companies of anti-competitive conduct

24 May 2019 Four pharmaceutical companies allegedly agreed not to compete for the supply of an anti-nausea tablet to the National Health Service, according to objections filed by the UK Competition and Markets Authority.

More on this story

CMA alleges collusion allowed 1,800% hike in Aspen drug pricing

9 October 2019 African drugmaker Aspen was able to increase its prices for fludrocortisone acetate tablets by 1,800% in the UK, as a result of collusion with two other firms, according to the UK’s Competition and Markets Authority.

CMA accuses 4 pharma companies of anti-competitive conduct

24 May 2019 Four pharmaceutical companies allegedly agreed not to compete for the supply of an anti-nausea tablet to the National Health Service, according to objections filed by the UK Competition and Markets Authority.

More features

In-house with Bayer: ‘Focus on quality early and stay close to inventors’

Explainer: ARIPO’s role in Plant Variety Protection

J&J sues over schizophrenia drug generic following patent victory

WATCH: The transparency tightrope—balancing innovation, regulation, and IP protection in a new era

Chicago firm Much Shelist adds partner with ‘entrepreneurial mindset’

Powell Gilbert launches Düsseldorf office with leading patent litigator

Startups toolkit: Why investors want more than patents

J&J fends off generic schizophrenia drug bids